Holen Sie sich die Stockscreener-App
3.57
3.39%
-0.12
Schlusskurs vom Vortag:
$3.69
Offen:
$3.7
24-Stunden-Volumen:
599.54K
Relative Volume:
0.29
Marktkapitalisierung:
$579.95M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
89.25
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
-3.91%
1M Leistung:
+23.36%
6M Leistung:
+393.97%
1J Leistung:
-3.39%
1-Tages-Spanne:
$3.50
$3.85
1-Wochen-Bereich:
$3.22
$3.85
52-Wochen-Spanne:
$0.5271
$5.1288
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.565 | 600.28M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
118.26 | 52.03B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.50 | 45.40B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.595 | 42.13B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.67 | 34.19B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
483.92 | 20.88B | 3.08B | 1.24B | 1.07B | 25.61 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? - Yahoo Finance
Can Ironwood Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Ironwood Pharmaceuticals (IRWD) Price Target Increased by 38.89% to 2.55 - Nasdaq
Can Ironwood Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5%Time to Sell? - MarketBeat
Is Ironwood Pharmaceuticals Inc. (I76) stock cheap by valuation metricsOptions Play & Scalable Portfolio Growth Ideas - Newser
Can Ironwood Pharmaceuticals Inc. stock sustain institutional interestProfit Target & Fast Gaining Stock Strategy Reports - Newser
Zacks Research Analysts Increase Earnings Estimates for IRWD - MarketBeat
Why Ironwood Pharmaceuticals Inc. (I76) stock could be next leaderJuly 2025 Macro Moves & Community Verified Swing Trade Signals - Newser
How dovish Fed policy supports Ironwood Pharmaceuticals Inc. (I76) stockRecession Risk & Weekly High Return Forecasts - Newser
Irritable Bowel Syndrome (IBS) Treatment Market Competition Analysis 2025: How Players Are Shaping Growth - EIN News
IRWD SEC FilingsIronwood 10-K, 10-Q, 8-K Forms - Stock Titan
Is Ironwood Pharmaceuticals, Inc. overvalued or undervalued? - Markets Mojo
How Ironwood Pharmaceuticals Inc. (I76) stock trades under stagflationLayoff News & Fast Momentum Entry Tips - Newser
Volume Summary: Can Ironwood Pharmaceuticals Inc stock deliver 10 annual returns2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - BỘ NỘI VỤ
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 4.5% HigherTime to Buy? - MarketBeat
Ironwood Pharmaceuticals (IRWD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Universal Beteiligungs und Servicegesellschaft mbH Buys 108,822 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
What Catalysts Are Shaping the Changing Narrative for Ironwood Pharmaceuticals? - Yahoo Finance
Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations - Finviz
Ironwood Pharma’s LINZESS® Price Set by HHS - MSN
Ironwood Pharmaceuticals chief legal officer sells shares worth $68,530 - MSN
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? - sharewise.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap UpHere's Why - MarketBeat
Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous H1 2025 (IRWD) - Seeking Alpha
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On WednesdayArrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL) - Benzinga
Ironwood Pharmaceuticals IncHHS releases maximum fair price for LinzessSEC filing - marketscreener.com
IRONWOOD PHARMACEUTICALS INC Announces LINZESS Price Update - TradingView
IRWD: LINZESS Medicare net price to be $136 from 2027 - Stock Titan
Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates - MSN
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3? - sharewise.com
How Ironwood Pharmaceuticals Inc. (I76) stock moves on employment data2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Will Ironwood Pharmaceuticals Inc. stock outperform Dow Jones indexMarket Activity Report & Smart Swing Trading Techniques - newser.com
Published on: 2025-11-21 02:18:04 - newser.com
How Ironwood Pharmaceuticals Inc. stock benefits from strong dollarJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Is Ironwood Pharmaceuticals Inc. (I76) stock attractive for dividend growthJuly 2025 Review & Capital Protection Trading Alerts - newser.com
How Ironwood Pharmaceuticals Inc. stock compares to industry benchmarksWeekly Trade Recap & Low Risk Profit Maximizing Plans - newser.com
Is Ironwood Pharmaceuticals Inc. stock a dividend growth opportunityMarket Growth Report & Smart Allocation Stock Tips - newser.com
VP Gaskins Surrenders 6,016 Of Ironwood Pharmaceuticals Inc [IRWD] - TradingView
[Form 4] IRONWOOD PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Can Ironwood Pharmaceuticals Inc. (I76) stock deliver strong annual returnsWeekly Volume Report & AI Forecast for Swing Trade Picks - newser.com
Can Ironwood Pharmaceuticals Inc. stock deliver strong Q4 earningsMarket Sentiment Summary & Fast Moving Stock Trade Plans - newser.com
Will earnings trigger a reversal in Ironwood Pharmaceuticals Inc.2025 Price Momentum & AI Enhanced Trading Signals - newser.com
Will breakout in Ironwood Pharmaceuticals Inc. lead to full recoveryMarket Activity Report & Real-Time Market Trend Scan - newser.com
Can Ironwood Pharmaceuticals Inc. stock continue upward trendDip Buying & Intraday High Probability Setup Alerts - newser.com
Price momentum metrics for Ironwood Pharmaceuticals Inc. explainedQuarterly Portfolio Report & Safe Investment Capital Preservation Plans - newser.com
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):